Background: Nedaplatin is a new analogue of cisplatin with similar efficacy but less renal toxicity. We investigated the appropriate dose of nedaplatin in combination with cyclophosphamide for patients with gynecological malignancies. Methods: Nine patients (five with ovarian cancer and four with uterine cervical cancer) were studied. Three patients received 60 mg/m2 of nedaplatin combined with 500 mg/m2 of cyclophosphamide every 4 weeks. Another three patients were each administered 80 or 100 mg/m2 of nedaplatin with the same dose of cyclophosphamide. A total of 27 courses was given. Results: No patient needed dose reduction due to myelosuppression and no severe adverse events were observed. Conclusions: Treatment with 100 mg/m2 of nedaplatin and 500 mg/m2 of cyclophosphamide is feasible for patients with gynecological malignancies. However, phase II studies are needed to clarify the efficacy of this combination chemotherapy. © 1999 Foundation for Promotion of Cancer Research.
CITATION STYLE
Ito, K., Adachi, S., Itani, Y., Koyama, M., Hori, K., Chin, R., … Saito, K. (1999). A dose-finding study of nedaplatin and cyclophosphamide for patients with gynecological malignancies. Japanese Journal of Clinical Oncology, 29(6), 299–302. https://doi.org/10.1093/jjco/29.6.299
Mendeley helps you to discover research relevant for your work.